Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

The Honey Pot Company, LLC ('The Honey Pot Co.” or 'the Company”), a leading 'better-for-you” feminine care brand and ...

We cannot give in to those questioning the value of multiculturalism and a society that cherishes diversity ...

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...

The Army opened a new kind of dining facility at Fort Hood, Texas, this month, replacing the traditional chow hall model with something closer to a university food court.

Investing.com -- Compass Pathways Plc (NASDAQ:CMPS) stock surged 33.7% on Tuesday following the announcement of highly statistically significant results from its second Phase 3 trial for COMP360, a ...

FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--MDT, a CUSO that helps credit unions navigate complex financial technology ecosystems, today announced the launch of its MDT Compass App, a cloud-based ...

Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...